GRT Capital Partners L.L.C. Continues to Hold Holdings in Flexion Therapeutics, Inc. (FLXN)

GRT Capital Partners L.L.C. maintained its stake in shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) during the 2nd quarter, according to its most recent filing with the SEC. The fund owned 11,428 shares of the specialty pharmaceutical company’s stock at the close of the 2nd quarter. GRT Capital Partners L.L.C.’s holdings in Flexion Therapeutics were worth $231,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the company. Schwab Charles Investment Management Inc. lifted its position in shares of Flexion Therapeutics by 0.5% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 101,214 shares of the specialty pharmaceutical company’s stock worth $2,047,000 after buying an additional 513 shares during the last quarter. IFP Advisors Inc lifted its position in shares of Flexion Therapeutics by 24.5% during the 2nd quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 1,000 shares during the last quarter. Teachers Advisors LLC lifted its position in shares of Flexion Therapeutics by 3.1% during the 1st quarter. Teachers Advisors LLC now owns 44,796 shares of the specialty pharmaceutical company’s stock worth $1,205,000 after buying an additional 1,328 shares during the last quarter. Alps Advisors Inc. lifted its position in shares of Flexion Therapeutics by 7.1% during the 2nd quarter. Alps Advisors Inc. now owns 28,666 shares of the specialty pharmaceutical company’s stock worth $580,000 after buying an additional 1,888 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. lifted its position in shares of Flexion Therapeutics by 5.7% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 55,853 shares of the specialty pharmaceutical company’s stock worth $1,503,000 after buying an additional 3,003 shares during the last quarter. Institutional investors and hedge funds own 82.75% of the company’s stock.

Flexion Therapeutics, Inc. (FLXN) opened at 23.64 on Friday. The firm’s market capitalization is $754.23 million. The stock has a 50 day moving average of $23.24 and a 200-day moving average of $21.99. Flexion Therapeutics, Inc. has a one year low of $15.88 and a one year high of $29.41.

Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.11). On average, equities analysts predict that Flexion Therapeutics, Inc. will post ($3.70) EPS for the current year.

Several analysts have recently weighed in on the stock. Needham & Company LLC restated a “buy” rating and set a $36.00 price objective (up previously from $34.00) on shares of Flexion Therapeutics in a research report on Thursday, August 10th. Royal Bank Of Canada restated an “outperform” rating and set a $44.00 price objective on shares of Flexion Therapeutics in a research report on Thursday, August 10th. BMO Capital Markets restated a “buy” rating on shares of Flexion Therapeutics in a research report on Friday, August 11th. ValuEngine upgraded shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Zacks Investment Research upgraded shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $31.50.

ILLEGAL ACTIVITY WARNING: “GRT Capital Partners L.L.C. Continues to Hold Holdings in Flexion Therapeutics, Inc. (FLXN)” was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.chaffeybreeze.com/2017/09/15/grt-capital-partners-l-l-c-continues-to-hold-holdings-in-flexion-therapeutics-inc-flxn.html.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply